1
EXHIBIT 99.4
AGREEMENT OF LIMITED PARTNERSHIP
of
ICOS-TEXAS BIOTECHNOLOGY L.P.
among
ICOS-ET-LP LLC and
TEXAS BIOTECHNOLOGY CORPORATION,
as Limited Partners,
and
ICOS-ET-GP LLC and
TBC-ET, Inc.,
as General Partners.
Effective as of
June 6, 2000
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-1-
2
TABLE OF CONTENTS
ARTICLE 1 DEFINITIONS; INTERPRETATION....................................................................2
1.1 Definitions............................................................................2
1.2 Interpretation.........................................................................8
ARTICLE 2 GENERAL PROVISIONS.............................................................................8
2.1 Name...................................................................................8
2.2 Principal Place of Business; Registered Office and Agent...............................8
2.3 Certificate of Limited Partnership.....................................................8
2.4 Term...................................................................................9
2.5 Purpose................................................................................9
2.5.1 Principal Purposes............................................................9
2.5.2 Commitment to [ * ]...........................................................9
2.6 Title to Partnership Property.........................................................10
2.7 Confidentiality.......................................................................10
2.8 Press Releases........................................................................11
ARTICLE 3 CAPITAL.......................................................................................11
3.1 Initial Capital Contributions.........................................................11
3.2 [ * ] Contribution of Background Technology...........................................11
3.2.1 [ * ]........................................................................11
3.2.2 TBC's Initial [ * ] Capital Contribution of Background Technology............11
(a) Transfer Pursuant to Endothelin License Agreement...................11
(b) [ * ]...............................................................12
(c) [ * ]...............................................................12
(d) Basis Allocation....................................................12
3.2.3 Additional Capital Contributions [ * ].......................................12
3.3 Management Committee Declared Capital Calls...........................................12
3.3.1 Capital Calls................................................................12
3.3.2 Defaulting Partner...........................................................12
3.4 [ * ] Research Payments and Royalties.................................................13
3.5 No Withdrawal of Capital; No Interest on Capital......................................13
ARTICLE 4 TAX PROVISIONS................................................................................13
4.1 Maintenance of Capital Accounts.......................................................13
4.2 Allocation of Profits.................................................................14
4.3 Allocation of Losses..................................................................14
4.4 Special Allocations...................................................................14
4.4.1 Minimum Gain Chargeback......................................................14
4.4.2 Partner Minimum Gain Chargeback..............................................15
4.4.3 Qualified Income Offset......................................................15
4.4.4 Gross Income Allocation......................................................15
4.4.5 Nonrecourse Deductions.......................................................16
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-i-
3
4.4.6 Partner Nonrecourse Deductions...............................................16
4.4.7 Code Section 754 Adjustments.................................................16
4.4.8 Allocations Relating to Taxable Issuance of Interests........................16
4.5 [ * ].................................................................................16
4.6 Code Section 704(c) Allocations.......................................................16
4.7 Other Allocations Rules...............................................................17
4.8 Tax Matters Partner...................................................................17
ARTICLE 5 DISTRIBUTIONS OF CASH.........................................................................18
5.1 Distributions.........................................................................18
5.1.1 Limitations..................................................................18
5.1.2 Amount of Distributions......................................................18
5.1.3 Timing of Distributions......................................................19
5.2 Additional Limitations on Distributions...............................................19
5.3 [ * ].................................................................................19
5.4 Distribution to Pay Taxes.............................................................19
ARTICLE 6 MANAGEMENT AND OPERATION......................................................................19
6.1 Management of the Partnership.........................................................19
6.1.1 General Partners.............................................................19
6.1.2 Limited Partners.............................................................20
6.2 Appointment of Committee Members......................................................20
6.3 Performance of Duties.................................................................20
6.4 Devotion of Time......................................................................21
6.5 Meetings of the Management Committee..................................................21
6.6 Action by Committee Members Without a Meeting.........................................21
6.7 Quorum and Voting at Meetings of Committee Members....................................21
6.8 Officers; Teams/Committees............................................................22
6.9 Internal Controls.....................................................................22
6.10 Financial and Business Information and Tax Returns....................................23
6.11 Bank Accounts.........................................................................23
6.12 Independent Enterprise................................................................23
6.13 Compensation..........................................................................23
6.14 Fiduciary Duty........................................................................24
6.15 Other Activities......................................................................24
6.16 Noncompetition........................................................................24
6.17 Conflicts of Interest.................................................................24
6.18 Patents...............................................................................25
6.19 Operations Outside the United States..................................................25
6.20 Trademarks............................................................................25
6.21 Responsible Party for Regulatory Purposes.............................................25
6.22 Marketing, Co-Promotion and Sales.....................................................25
6.23 Manufacturing.........................................................................25
6.24 Regulatory Matters....................................................................26
ARTICLE 7 RIGHTS, OBLIGATIONS AND POWERS OF THE MEMBERS.................................................26
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-ii-
4
7.1 Compensation of Partners..............................................................26
7.2 Services..............................................................................26
7.2.1 Types of Services............................................................26
7.2.2 Charges for Services.........................................................26
7.3 Admission of Additional Partners......................................................27
ARTICLE 8 LIMITATION UPON LIABILITY; INDEMNIFICATION....................................................27
8.1 Limitation Upon Liability of Limited Partners.........................................27
8.2 Indemnification by Partnership........................................................27
ARTICLE 9 REPRESENTATIONS AND WARRANTIES................................................................28
9.1 Representations and Warranties........................................................28
9.1.1 Organization and Existence...................................................28
9.1.2 Power and Authority..........................................................28
9.1.3 Authorization and Enforceability.............................................28
9.1.4 No Governmental Consents.....................................................28
9.1.5 No Conflict or Breach........................................................28
9.1.6 No Proceedings...............................................................29
9.1.7 No Endothelin Agents.........................................................29
9.2 Additional Representations and Warranties of TBC......................................29
9.3 Warranty of Statements................................................................29
9.4 Survival of Representations and Warranties............................................30
ARTICLE 10 INDEMNIFICATION..............................................................................30
10.1 Indemnification.......................................................................30
10.2 Mechanism for Indemnification.........................................................30
ARTICLE 11 DISPUTE RESOLUTION...........................................................................31
11.1 Dispute...............................................................................31
11.2 Mediation.............................................................................31
ARTICLE 12 TRANSFERS OF MEMBERSHIP INTERESTS............................................................31
12.1 Overall Restrictions..................................................................31
12.2 Additional Restrictions on the Limited Partners.......................................32
12.2.1 Event Involving ICOS-LP......................................................32
12.2.2 Event Involving TBC..........................................................32
12.3 Purchase Price and Payment Date.......................................................32
12.4 Change in Control.....................................................................33
12.4.1 ICOS-LP......................................................................33
12.4.2 TBC..........................................................................33
12.4.3 Definition...................................................................33
12.5 Admission of Substituted Partners.....................................................33
12.6 Specific Performance..................................................................34
ARTICLE 13 SALE, DISSOLUTION AND LIQUIDATION............................................................34
13.1 Events of Dissolution.................................................................34
13.2 Final Accounting and Tax Returns......................................................35
13.3 Liquidation...........................................................................35
13.4 Distributions in Liquidation..........................................................35
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-iii-
5
13.5 Deficit Capital Accounts..............................................................36
13.6 Termination of Partnership and Agreement..............................................37
ARTICLE 14 ACCOUNTING AND REPORTS.......................................................................37
14.1 Books and Records.....................................................................37
14.2 Accounting Method.....................................................................38
14.3 Fiscal Year...........................................................................38
14.4 Reports; Tax Returns..................................................................38
14.5 Required Governmental Filings.........................................................39
ARTICLE 15 GENERAL PROVISIONS...........................................................................39
15.1 Notices...............................................................................39
15.2 Waiver................................................................................40
15.3 Severability..........................................................................41
15.4 Waiver of Partition...................................................................41
15.5 Further Assurances....................................................................41
15.6 Governing Law.........................................................................41
15.7 Counterparts..........................................................................41
15.8 Limitation on Rights of Others........................................................41
15.9 Successors and Assigns................................................................42
15.10 Entire Agreement; Amendment...........................................................42
15.11 Expenses..............................................................................42
15.12 Construction..........................................................................42
15.13 Disclaimer of Agency..................................................................42
15.14 Rights and Remedies...................................................................42
15.15 Attorneys' Fees.......................................................................43
EXHIBIT A ENDOTHELIN LICENSE AGREEMENT...................................................................1
EXHIBIT B RESEARCH AND DEVELOPMENT SERVICE AGREEMENT.....................................................1
EXHIBIT C PRESS RELEASE..................................................................................1
EXHIBIT D SCHEDULE OF [ * ] PAYMENTS.....................................................................1
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-iv-
6
AGREEMENT OF LIMITED PARTNERSHIP
OF
ICOS-TEXAS BIOTECHNOLOGY L.P.
THIS AGREEMENT OF LIMITED PARTNERSHIP (this "Agreement") of ICOS-TEXAS
BIOTECHNOLOGY L.P. (the "Partnership") is entered into effective as of this 6th
day of June 2000 (the "Effective Date") by and between ICOS-ET-LP LLC, a
Washington limited liability company ("ICOS-LP"), and TEXAS BIOTECHNOLOGY
CORPORATION, a Delaware corporation ("TBC"), as the Limited Partners; and
ICOS-ET-GP LLC, a Washington limited liability company ("ICOS-GP"), and TBC-ET,
Inc., a Delaware corporation ("TBC-GP"), as the General Partners. The Limited
Partners and General Partners are referred to hereafter collectively as the
"Partners."
RECITALS
A. TBC has conducted research, has developed and possesses
certain existing proprietary patent rights, technical information, technology
and know-how relating to Endothelin Agents and their ligands.
B. The Partners believe that the aforementioned patent rights,
information, technology and know-how will have important application to the
development of products.
C. The Partners formed the Partnership for the principal purpose
of developing, manufacturing, producing and selling throughout the Territory on
a commercial basis Endothelin Products.
D. TBC intends to license to the Partnership its technology
related to Endothelin Agents for use in the Field in partial consideration for a
Partnership Interest in the Partnership as more fully set forth herein.
E. ICOS-LP, ICOS-GP and TBC-GP each intend to contribute cash to
the Partnership in consideration for Partnership Interests in the Partnership as
more fully set forth herein.
F. The Partners believe that it is in their best interest to set
forth their mutual understanding with respect to, among other things, management
and operation of the Partnership and the ownership and Transfer of the
Partnership Interests.
NOW, THEREFORE, in consideration of the mutual covenants of the
parties, each to the other, and of good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
7
ARTICLE 1
DEFINITIONS; INTERPRETATION
1.1 DEFINITIONS
Capitalized terms used herein shall have the following meanings:
"Act" means the Delaware Revised Uniform Limited Partnership Act, as
provided in Title 6, Chapter 17 of the Delaware Code, Section 101 et. seq., as
amended from time to time.
"Adjusted Capital Account Deficit" means, with respect to any Partner,
the deficit balance, if any, in such Partner's Capital Account as of the end of
the relevant Fiscal Year, after giving effect to the following adjustments:
(a) Credit to such Capital Account any amounts that such
Partner is obligated to restore pursuant to any provision of this Agreement or
is deemed to be obligated to restore pursuant to the penultimate sentences of
Regulations Sections 1.704-2(g)(1) and 1.704-2(i)(5); and
(b) Debit to such Capital Account the items described in
Regulations Sections 1.704-l(b)(2)(ii)(d)(4), 1.704-l(b)(2)(ii)(d)(5) and
1.704-l(b)(2)(ii)(d)(6).
The foregoing definition of Adjusted Capital Account Deficit is
intended to comply with the provisions of Regulations Section
1.704-l(b)(2)(ii)(d) and shall be interpreted consistently therewith.
"Affiliate" means, with respect to any Person, another Person that,
directly or indirectly, controls, is controlled by or is under common control
with such Person. The term "control" means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and
policies of a Person, whether through the ownership of voting securities, by
contract or otherwise. The direct or indirect ownership of [ * ] or, if smaller,
the maximum allowed by applicable law, of the voting securities of a business
entity or of an interest in the assets, profits or earnings of an Entity shall
be deemed to constitute "control" of the Entity.
"Agreement" means this Agreement of Limited Partnership, including all
exhibits attached hereto, as originally executed and as amended from time to
time.
"Background Technology" shall have the meaning set forth in the
Endothelin License Agreement. The Background Technology consists of proprietary
technical information, technology and know-how, including patents, patent
applications and copyrights, owned or controlled by TBC as of the Effective Date
that relate to Endothelin Agents and that are required in the development,
manufacture, production, use or sale of Endothelin Products. The
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-2-
8
Background Technology is being licensed to the Partnership effective as of the
Effective Date pursuant to the Endothelin License Agreement.
"Capital Account" means the capital account to be determined and
maintained for each Partner pursuant to Section 4.1 throughout the existence of
the Partnership, which shall be interpreted and applied in a manner consistent
with Regulations Section 1.704-1(b).
"Capital Contribution" means, with respect to any Partner, the amount
of money and the initial Gross Asset Value of any property (other than money)
contributed to the Partnership with respect to the Partnership Interest held by
such Partner reduced by the amount of any liabilities of such Partner assumed by
the Partnership in connection with such Capital Contribution or that is secured
by any property contributed by such Partner as a part of such Capital
Contribution.
"Certificate of Limited Partnership" has the meaning set forth in
Section 2.3.
"Chair" means the chairperson of the Management Committee as appointed
in Section 6.2.
"Change in Control" has the meaning set forth in Section 12.4.3.
"Code" means the Internal Revenue Code of 1986, as amended.
"Committee Member" means a person appointed to the Management Committee
pursuant to Article 6.
"Depreciation" means, for each Fiscal Year, an amount equal to the
depreciation, amortization or other cost recovery deduction allowable with
respect to an asset for such Fiscal Year, except that if the Gross Asset Value
of an asset differs from its adjusted basis for federal income tax purposes as
of the beginning of such Fiscal Year, Depreciation shall be an amount that bears
the same ratio to such beginning Gross Asset Value as the federal income tax
depreciation, amortization or other cost recovery deduction for such Fiscal Year
bears to such beginning adjusted tax basis; provided, however, that if the
adjusted basis for federal income tax purposes of an asset at the beginning of
such Fiscal Year is zero, Depreciation shall be determined with reference to
such beginning Gross Asset Value using any reasonable method selected by the
Management Committee.
"Effective Date" means the effective date of this Agreement as
indicated in the first paragraph hereof.
"Endothelin Agent" [ * ].
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-3-
9
"Endothelin License Agreement" means the license agreement to be
entered into between the Partnership and TBC as of the Effective Date, a copy of
which is attached hereto as Exhibit A.
"Endothelin Products" means [ * ].
"Endothelin Receptor" means [ * ].
"Endothelin Technology" shall have the same meaning as "Partnership
Technology" as set forth in the Research and Development Service Agreement.
"Entity" means any general partnership, limited partnership, limited
liability partnership, limited liability company, corporation, joint venture,
trust, estate, business trust, cooperative or association or any other
organization that is not a natural Person.
"EtRAs" means [ * ].
"Event of Withdrawal of a General Partner" means an event that causes a
Person to cease to be a general partner as provided in Section 17-402 of the
Act.
"Field" means [ * ].
"Fiscal Year" has the meaning set forth in Section 14.3.
"General Partners" means ICOS-GP and TBC-GP and all other Persons
admitted as additional or substituted general partners pursuant to this
Agreement, so long as they remain general partners.
"Gross Asset Value" means, with respect to any asset, the asset's
adjusted basis for federal income tax purposes, except as follows:
(a) The initial Gross Asset Value of any asset
contributed by a Partner to the Partnership shall be the gross fair market value
of such asset, as determined by the contributing Partner and the Management
Committee, provided that the initial Gross Asset Value of the assets contributed
to the Partnership pursuant to Article 3 shall be as set forth in such Article;
(b) The Gross Asset Values of Property shall be adjusted
to equal their respective gross fair market values, as determined by the
Management Committee, as of the following times: (i) the acquisition of an
additional Partnership Interest by any new or existing Partner in exchange for
more than a de minimis Capital Contribution; (ii) the distribution by the
Partnership to a Partner of more than a de minimis amount of Property as
consideration for an Interest; and (iii) the liquidation of the Partnership
within the meaning of Regulations Section 1.704-l(b)(2)(ii)(g); provided,
however, that the adjustments pursuant to clauses (i) and (ii) above
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-4-
10
shall be made only if the Management Committee reasonably determines that such
adjustments are necessary or appropriate to reflect the relative economic
interests of the Partners in the Partnership;
(c) The Gross Asset Value of any Property distributed to
any Partner shall be adjusted to equal the gross fair market value of such
Property on the date of distribution as determined by the distributee and the
Management Committee; and
(d) The Gross Asset Values of Property shall be increased
(or decreased) to reflect any adjustments to the adjusted basis of such assets
pursuant to Code Section 734(b) or Code Section 743(b), but only to the extent
that such adjustments are taken into account in determining Capital Accounts
pursuant to Regulations Section 1.704-l(b)(2)(iv)(m) and Section 4.1 hereof;
provided, however, that the Gross Asset Values shall not be adjusted pursuant to
this clause (d) to the extent the Management Committee determines that an
adjustment pursuant to clause (b) is necessary or appropriate in connection with
a transaction that would otherwise result in an adjustment pursuant to this
clause (d).
If the Gross Asset Value of an asset has been determined or adjusted pursuant to
clause (a), (b) or (d) above, such Gross Asset Value shall thereafter be used
for purposes of calculating Depreciation with respect to such asset for purposes
of determining Profits and Losses.
"ICOS Partners" means ICOS-LP and ICOS-GP collectively.
[ * ]
"IRS" means the Internal Revenue Service of the U.S. Department of the
Treasury.
"Limited Partners" means ICOS-LP and TBC and all other Persons admitted
as additional or substituted limited partners pursuant to this Agreement, so
long as they remain limited partners.
"Management Committee" means the Management Committee established in
accordance with Section 6.1.
[ * ]
"Nonrecourse Deductions" has the meaning set forth in Regulations
Section 1.704-2(b)(1).
"Nonrecourse Liability" has the meaning set forth in Regulations
Section 1.704-2(b)(3).
"Partner Nonrecourse Debt" has the meaning of "partner nonrecourse
debt" set forth in Regulations Section 1.704-2(b)(4).
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-5-
11
"Partner Nonrecourse Debt Minimum Gain" means an amount, with respect
to each Partner Nonrecourse Debt, equal to the Partnership Minimum Gain that
would result if such Partner Nonrecourse Debt were treated as a Nonrecourse
Liability determined in accordance with Regulations Section 1.704-2(i)(3).
"Partners" means the General Partners and the Limited Partners or their
respective successors and permitted assigns.
"Partnership" means ICOS-Texas Biotechnology L.P. formed pursuant to
the Certificate of Limited Partnership and governed by this Agreement.
"Partnership Interest" or "Interest" means the interest in the
Partnership representing each Partner's percentage ownership in, and share of
Profits and Losses of, and the right to receive distributions under Sections 5.1
and 13.4 from, the Partnership.
"Partnership Minimum Gain" has the meaning of "partnership minimum
gain" set forth in Regulations Sections 1.704-2(b)(2) and 1.704-2(d).
"Person" means any individual or Entity, and the heirs, executors,
administrators, legal representatives, successors and assigns of such Person
where the context so permits.
"Profits" and "Losses" mean the net taxable income and net tax loss of
the Partnership computed for each Fiscal Year or other relevant period, as
determined in accordance with Code Section 703(a) (for this purpose, all items
of income, gain, loss, or deduction required to be stated separately pursuant to
Code Section 703(a)(1) shall be included in taxable income or loss), with the
following adjustments:
(a) Any income of the Partnership that is exempt from
federal income tax and not otherwise taken into account in computing Profits and
Losses pursuant to this clause (a) shall be added to such taxable income or
loss;
(b) Any expenditures of the Partnership described in Code
Section 705(a)(2)(B) (including expenditures treated as described in Code
Section 705(a)(2)(B) under Regulations Section 1.704-l(b)(2)(iv)(i)), and not
otherwise taken into account in computing Profits and Losses pursuant to this
definition, shall be subtracted from such taxable income or loss;
(c) In the event the Gross Asset Value of any Partnership
asset is adjusted pursuant to the terms of this Agreement, the amount of such
adjustment shall be taken into account as gain or loss from the disposition of
such asset for purposes of computing Profits and Losses;
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-6-
12
(d) Gain or loss resulting from any disposition of
Property with respect to which gain or loss is recognized for federal income tax
purposes shall be computed by reference to the Gross Asset Value of the Property
disposed of, notwithstanding that the adjusted tax basis of such Property
differs from its Gross Asset Value;
(e) In lieu of the depreciation, amortization and other
cost recovery deductions taken into account in computing such taxable income or
loss, there shall be taken into account Depreciation for such Fiscal Year,
computed in accordance with the terms hereof;
(f) To the extent an adjustment to the adjusted tax basis
of any Property pursuant to Code Section 734(b) or Code Section 743(b) is
required pursuant to Regulations Section 1.704-l(b)(2)(iv)(m)(4) to be taken
into account in determining Capital Accounts as a result of a distribution other
than in liquidation of the Partner's interest, the amount of such adjustment
shall be treated as an item of gain (if the adjustment increases the basis of
the asset) or loss (if the adjustment decreases the basis of the asset) from the
disposition of the Property and shall be taken into account for purposes of
computing Profits or Losses; and
(g) Notwithstanding any other provisions of this
Agreement, any items that are specially allocated by the Partnership pursuant to
Section 4.4 or 4.5 shall not be taken into account in computing Profits or
Losses. The amount of the items of Partnership income, gain, loss or deduction
available to be specially allocated pursuant to Sections 4.4 and 4.5 shall be
determined by applying rules analogous to those set forth in this definition of
Profits and Losses.
"Property" means any real, personal, tangible or intangible property
contributed to or purchased, developed or otherwise acquired and owned by the
Partnership, including any improvements thereto.
"Regulations" means the income tax regulations promulgated under the
Code, as such regulations are amended from time to time (including corresponding
provisions of succeeding regulations).
"Research and Development Service Agreement" means the agreement to be
entered into among the Partnership, ICOS Corporation and TBC as of the Effective
Date, a copy of which is attached hereto as Exhibit B.
[ * ]
"TBC Partners" means TBC and TBC-GP collectively.
"Territory" means [ * ].
"Transfer" means any sale, assignment, exchange, pledge, encumbrance or
any other disposition of all or any part of a Partnership Interest, whether
voluntary or involuntary.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-7-
13
1.2 INTERPRETATION
(a) When required by the context, the singular includes the plural
and vice versa, and the masculine includes the feminine and neuter genders, and
vice versa;
(b) Except as otherwise specifically indicated, all references in
this Agreement to "Exhibits," "Schedules," "Articles," "Sections" and other
subdivisions are to the corresponding Exhibits, Schedules, Articles, Sections or
subdivisions of this Agreement as they may be amended from time to time; and
(c) Headings set forth in this Agreement are used for convenience
only and are not to be considered in construing or interpreting this Agreement.
ARTICLE 2
GENERAL PROVISIONS
2.1 NAME
The name of the Partnership shall be ICOS-Texas Biotechnology L.P. All
business of the Partnership shall be conducted under such name and under such
variations thereof as the General Partners deem necessary or appropriate to
comply with the requirements of law in any jurisdiction in which the Partnership
may elect to do business.
2.2 PRINCIPAL PLACE OF BUSINESS; REGISTERED OFFICE AND AGENT
(a) The address and principal place of business of the Partnership
shall be ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇, or at such other place as the
Management Committee may from time to time determine.
(b) The registered office of the Partnership in the State of
Delaware is located at ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇. The registered
agent of the Partnership to accept service of process is The Corporation Trust
Company.
2.3 CERTIFICATE OF LIMITED PARTNERSHIP
The Partners shall form the Partnership under and pursuant to the Act
by filing a Certificate of Limited Partnership for the Partnership (the
"Certificate of Limited Partnership") with the Secretary of State of the State
of Delaware.
2.4 TERM
The term of the Partnership shall commence upon the filing of the
Certificate of Limited Partnership with the Secretary of State of the State of
Delaware and shall continue until dissolved in accordance with Article 13.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-8-
14
2.5 PURPOSE
2.5.1 PRINCIPAL PURPOSES
The purposes of the Partnership are to engage in the business
of developing, manufacturing, producing, promoting and selling throughout the
Territory within the Field Endothelin Products, to otherwise exploit the
Endothelin Technology for commercial purposes by whatever means and to do all
things necessary, appropriate or advisable in furtherance thereof. [ * ] The
Partnership shall not engage in any other business or activity without the
unanimous written agreement of the General Partners.
2.5.2 COMMITMENT TO [ * ]
The Partners agree that they will use commercially reasonable
best efforts under the Research and Development Service Agreement to cause the
Partnership to accomplish the following goals [ * ]
[ * ]
The Partners agree to commit the personnel, and create
development plans under the Research and Development Service Agreement and to
make Capital Contributions to the Partnership hereunder consistent with the
obligations hereunder to cause the Partnership to accomplish these goals [ * ]
provided, however, that it is recognized and agreed that the General Partners
may agree to change these goals and/or the time necessary to achieve these goals
and that no party will be in breach of this Section 2.5.2 if either goal cannot
be reasonably accomplished due to scientific, safety, efficacy, CMC or
regulatory developments.
In the event that either goal is not attained within [ * ] of
the Effective Date and a dispute arises between the General Partners concerning
[ * ] the Dispute shall be resolved in accordance with the terms and provisions
of this Section 2.5.2. No party shall have the right to litigate the Dispute in
any court, state or federal.
[ * ]
2.6 TITLE TO PARTNERSHIP PROPERTY
The Property shall be owned solely by the Partnership as an entity, and
no Partner, individually, shall have any ownership interest in any of the
Property.
2.7 CONFIDENTIALITY
(a) Each Partner agrees (i) to take all reasonable precautions and
to use its best efforts to maintain the confidentiality of all Confidential
Information that such Partner or any of its
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-9-
15
Affiliates (the "Recipient") obtains in respect to any other Partner, the
Partnership or any of their Affiliates (the "Disclosing Partner") and (ii) not
to use or disclose such Confidential Information to any third parties other than
as permitted by Section 2.7(b). For purposes of this Section 2.7, "Confidential
Information" means all proprietary or confidential information owned or provided
by a Disclosing Partner, including, but not limited to, proprietary or
confidential information provided under the two Confidential Disclosure
Agreements (CDAs) dated [ * ] and [ * ] between ICOS Corporation and TBC
regarding confidential information, other than information that (A) was
previously known to the Recipient (other than from a Disclosing Partner), or (B)
is available or, without the fault of the Recipient (other than the Partnership)
becomes available to the general public, or (C) is lawfully received by the
Recipient without an obligation of confidentiality from a third party that, to
the Recipient's knowledge, is not bound by any obligation of confidentiality.
The disclosure of Confidential Information shall not constitute any grant of any
license or any other rights or generate any business arrangements unless
specifically set forth herein or in another agreement.
(b) A Recipient may disclose Confidential Information (i) with the
prior written consent of the Disclosing Partner, (ii) to appropriate regulatory
authorities, attorneys and accountants and pursuant to any order of a court,
administrative agency or other governmental authority, or (iii) to take any
lawful action that it deems necessary to protect its interests or the interests
of its Affiliates under, or to enforce compliance with the terms and conditions
of, this Agreement; provided, however, that in the event a Recipient may become
legally compelled to disclose any Confidential Information it will promptly
consult with the Disclosing Partner as to the reasons for such disclosure and
will afford the Disclosing Partner a reasonable opportunity to obtain a
protective order as to such information and will use reasonable efforts to
obtain reliable assurance that the information disclosed will be treated
confidentially.
(c) This Section 2.7 shall supersede and cancel the two
Confidential Disclosure Agreements (CDAs) dated [ * ] and [ * ] between ICOS
Corporation and TBC regarding confidential information.
(d) This Section 2.7 shall survive this Agreement and shall
continue in full force and effect for a period of five (5) years after the
dissolution of the Partnership.
2.8 PRESS RELEASES
Attached hereto as Exhibit C is a form of press release that the
Partners intend to release upon execution of this Agreement or shortly
thereafter. All ▇▇▇▇▇▇ ▇▇▇▇▇ releases by any Partner relating to the subject
matter of this Agreement and related agreements shall be approved in advance by
each Partner after written notice of such press release is given to the other
Partners, except to the extent the press release is required by law in the
opinion of legal counsel to the Partner or the substance thereof has been
previously reviewed and released by the Partners or is
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-10-
16
in the public domain through no fault of the releasing Partner. The content and
timing of any notice of any ▇▇▇▇▇▇ ▇▇▇▇▇ release shall be reasonable under the
circumstances.
ARTICLE 3
CAPITAL
3.1 INITIAL CAPITAL CONTRIBUTIONS
Within ten (10) days of the Effective Date, (a) ICOS-GP shall make a
[ * ] Capital Contribution to the Partnership of [ * ], (b) TBC-GP shall make a
[ * ] Capital Contribution to the Partnership of [ * ], (c) ICOS-LP shall make a
[ * ] Capital Contribution to the Partnership of [ * ], and (d) TBC shall make a
Capital Contribution to the Partnership of [ * ] in the manner described in
Section 3.2.2(a) (collectively, the "Initial Capital Contributions"). In
exchange for their [ * ] contributions, ICOS-GP and TBC-GP will each receive a
one-tenth of one percent (0.1%) Partnership Interest. The Partnership Interests
of ICOS-LP and TBC are described below.
3.2 [ * ] CONTRIBUTION OF BACKGROUND TECHNOLOGY
3.2.1 [ * ]
In exchange for its [ * ] Initial Capital Contribution,
ICOS-LP shall receive a forty-nine and nine-tenths percent (49.9%) Partnership
Interest and shall have an initial Capital Account balance equal to [ * ]
3.2.2 TBC'S INITIAL [ * ] CAPITAL CONTRIBUTION OF BACKGROUND
TECHNOLOGY
(a) TRANSFER PURSUANT TO ENDOTHELIN LICENSE AGREEMENT
TBC shall transfer to the Partnership the Endothelin
License Agreement pursuant to which the Partnership (as licensee) shall receive
a license to the Background Technology. Notwithstanding the use of the
Endothelin License Agreement to effect the transfer, the parties agree that TBC
has transferred ownership, for U.S. federal income tax purposes, of the
Background Technology that is licensed exclusively to the Partnership.
(b) [ * ]
(c) [ * ]
In exchange for its Initial Capital Contribution, TBC
shall receive: (i) the [ * ] and (ii) a forty-nine and nine-tenths percent
(49.9%) Partnership Interest and shall have an initial Capital Account balance
of [ * ]
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-11-
17
(d) BASIS ALLOCATION
[ * ]
3.2.3 ADDITIONAL CAPITAL CONTRIBUTIONS [ * ]
ICOS-LP shall make additional Capital Contributions of up to [
* ] in the aggregate in accordance with the terms of Exhibit D attached hereto
(each such payment, a [ * ]. Upon ICOS-LP's making each [ * ], ICOS-LP's Capital
Account balance shall be increased by the dollar amount of such payment. [ * ]
3.3 MANAGEMENT COMMITTEE DECLARED CAPITAL CALLS
3.3.1 CAPITAL CALLS
Upon each party's contribution of its Initial Capital
Contributions as required in Sections 3.1, the Management Committee, in its sole
discretion, may from time to time require each Limited Partner to make
additional Capital Contributions to the Partnership to fund activities (a
"Capital Call"). To make a Capital Call, the Management Committee shall give
written notice to each Limited Partner at least ninety (90) business days prior
to the due date for making such additional Capital Contribution. Such notice
shall contain the following information: (a) the total capital to be
contributed; (b) the amount owed by each Limited Partner; and (c) the date on
which such amount is due (the "Due Date"). Each Limited Partner shall be
required to contribute only an amount of the Capital Call equal to such
Partner's percentage ownership interest in the Partnership relative to the
ownership interests owned by all Limited Partners, and shall fund its Capital
Contributions in cash.
3.3.2 DEFAULTING PARTNER
If a Limited Partner (the "Defaulting Partner") does not
contribute all of its respective share of any Capital Call (the difference
between its share and the amount contributed, the "Default Amount") on or before
the Due Date, the Partnership shall, [ * ]
3.4 [ * ] RESEARCH PAYMENTS AND ROYALTIES
[ * ]
3.5 NO WITHDRAWAL OF CAPITAL; NO INTEREST ON CAPITAL
No Partner shall be entitled to withdraw or demand the return of any
part of such Partner's Capital Contributions, except as provided in Section
3.3.2 or Article 13. No Partner shall have the right to receive interest on its
Capital Contribution or its Capital Account.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-12-
18
ARTICLE 4
TAX PROVISIONS
4.1 MAINTENANCE OF CAPITAL ACCOUNTS
A Capital Account shall be established and maintained for each Partner
in accordance with the following provisions:
(a) Each Partner's Capital Account shall be increased by
(i) the amount of such Partner's Capital Contribution, (ii) such Partner's
allocable share of Profits and any items of the nature of income or gain that
are specially allocated pursuant to Section 4.4 or 4.5, and (iii) the amount of
any Partnership liabilities assumed by such Partner or that are secured by any
Property distributed to such Partner. [ * ]
(b) Each Partner's Capital Account shall be decreased by
(i) the amount of cash and the Gross Asset Value of any Property distributed to
such Partner pursuant to any provision of this Agreement, (ii) such Partner's
distributable share of Losses and any items in the nature of expenses or losses
that are specially allocated pursuant to Section 4.4 or 4.5, and (iii) the
amount of any liabilities of such Partner assumed by the Partnership or that are
secured by any property contributed by such Partner to the Partnership.
(c) Upon the Transfer of all or part of an Interest, the
Capital Account of the transferor that is attributable to the transferred
Interest shall carry over to the transferee Partner in accordance with the
provisions of Regulations Section 1.704-l(b)(2)(iv)(1), except as otherwise
required to satisfy Regulations Section 1.704-l(b) in connection with a
termination of the Partnership.
(d) In determining the amount of any liability for
purposes of maintaining Capital Accounts for the Partners, there shall be taken
into account Code Section 752(c) and any other applicable provisions of the Code
and the Regulations.
In the event the Management Committee shall determine that it is
prudent to modify the manner in which the Capital Accounts, or any debits or
credits thereto (including, without limitation, debits or credits relating to
liabilities that are secured by contributed or distributed Property or that are
assumed by the Partnership or the Partners), are computed in order to comply
with the Code and the Regulations, the Management Committee may make such
modification, provided that it is not likely to have any material effect on the
amounts distributable to any Partner pursuant to Article 13 upon the dissolution
of the Partnership. The Management Committee also shall make (i) any adjustments
that are necessary or appropriate to maintain equality between (A) the Capital
Accounts of the Partners and (B) the amount of Partnership capital reflected on
the Partnership's balance sheet, as computed for book purposes, in accordance
with Regulations Section 1.704-1(b)(2)(iv)(g) and (ii) any appropriate
modifications
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-13-
19
in the event unanticipated events might otherwise cause this Agreement not to
comply with Regulations Section 1.704-1(b).
4.2 ALLOCATION OF PROFITS
After giving effect to the special allocations set forth in Sections
4.4 and 4.5, Profits for any Fiscal Year shall be allocated among the Partners
in proportion to their respective Partnership Interests.
4.3 ALLOCATION OF LOSSES
After giving effect to the special allocations set forth in Sections
4.4 and 4.5, Losses for any Fiscal Year shall be allocated among the Partners in
proportion to their respective Partnership Interests.
4.4 SPECIAL ALLOCATIONS
The following special allocations shall be made in the following order
and priority:
4.4.1 MINIMUM GAIN CHARGEBACK
Except as otherwise provided in Regulations Section
1.704-2(f), notwithstanding any other provision of this Article 4, if there is a
net decrease in Partnership Minimum Gain during any Fiscal Year, each Partner
shall be specially allocated items of Partnership income and gain for such
Fiscal Year (and if necessary subsequent Fiscal Years) in an amount equal to
such Partner's share of the net decrease in Partnership Minimum Gain, determined
in accordance with Regulations Section 1.704-2(g). Allocations pursuant to the
previous sentence shall be made in proportion to the respective amounts required
to be allocated to each Partner pursuant thereto. The items to be so allocated
shall be determined in accordance with Regulations Sections 1.704-2(f)(6) and
1.704-2(j)(2). This Section 4.4.1 is intended to comply with the minimum gain
chargeback requirement in Regulations Section 1.704-2(f) and shall be
interpreted consistently therewith.
4.4.2 PARTNER MINIMUM GAIN CHARGEBACK
Except as otherwise provided in Regulations Section
1.704-2(i)(4), notwithstanding any other provision of this Article 4, if there
is a net decrease in Partner Nonrecourse Debt Minimum Gain attributable to a
Partner Nonrecourse Debt during any Fiscal Year, each Partner who has a share of
the Partner Nonrecourse Debt Minimum Gain attributable to such Partner
Nonrecourse Debt, determined in accordance with Regulations Section
1.704-2(i)(5), shall be specially allocated items of Partnership income and gain
for such Fiscal Year (and, if necessary, subsequent Fiscal Years) in an amount
equal to such Partner's share of the net decrease in Partner Nonrecourse Debt
Minimum Gain attributable to such Partner
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-14-
20
Nonrecourse Debt, determined in accordance with Regulations Section
1.704-2(i)(4). Allocations pursuant to the previous sentence shall be made in
proportion to the respective amounts required to be allocated to each Partner
pursuant thereto. The items to be so allocated shall be determined in accordance
with Regulations Sections 1.704-2(i)(4) and 1.704-2(j)(2). This Section 4.4.2 is
intended to comply with the minimum gain chargeback requirement in Regulations
Section 1.704-2(i)(4) and shall be interpreted consistently therewith.
4.4.3 QUALIFIED INCOME OFFSET
In the event any Partner unexpectedly receives any
adjustments, allocations or distributions described in Regulations Section
1.704-1(b)(2)(ii)(d)(4), Section 1.704-1(b)(2)(ii)(d)(5) or Section
1.704-1(b)(2)(ii)(d)(6), items of Partnership income and gain shall be
specifically allocated to such Partner in an amount and manner sufficient to
eliminate, to the extent required by the Regulations, the Adjusted Capital
Account Deficit of such Partner as quickly as possible, provided that an
allocation pursuant to this Section 4.4.3 shall be made only if and to the
extent that such Partner would have an Adjusted Capital Account Deficit after
all other allocations provided for in this Section 4 have been tentatively made
as if this Section 4.4.3 were not in this Agreement.
4.4.4 GROSS INCOME ALLOCATION
In the event any Partner has a deficit Capital Account at the
end of any Fiscal Year that is in excess of the sum of (a) the amount such
Partner is obligated to restore pursuant to any provision of this Agreement and
(b) the amount such Partner is deemed to be obligated to restore pursuant to the
penultimate sentences of Regulation Sections 1.704-2(g)(1) and 1.704-2(i)(5),
such Partner shall be specially allocated items of Partnership income and gain
in the amount of such excess as quickly as possible, provided that an allocation
pursuant to this Section 4.4.4 shall be made only if and to the extent that such
Partner would have a deficit Capital Account in excess of such sum after all
other allocations provided for in this Section 4 have been made as if Section
4.4.3 and this Section 4.4.4 were not in this Agreement.
4.4.5 NONRECOURSE DEDUCTIONS
Nonrecourse Deductions for any Fiscal Year shall be specially
allocated among the Partners in proportion to their Partnership Interests.
4.4.6 PARTNER NONRECOURSE DEDUCTIONS
Any Nonrecourse Deductions for any Fiscal Year shall be
specially allocated to the Partner who bears the economic risk of loss with
respect to the Nonrecourse Debt to which such Nonrecourse Deductions are
attributable in accordance with Regulations Section 1.704-2(i)(1).
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-15-
21
4.4.7 CODE SECTION 754 ADJUSTMENTS
In the event a Partnership Interest is Transferred or Property
is distributed to a Partner, the Management Committee shall, upon the written
request of any General Partner, elect to cause the basis of the Property to be
adjusted for federal income tax purposes under Sections 734, 743 and 754 of the
Code. To the extent an adjustment to the adjusted tax basis of any Partnership
asset pursuant to Code Section 734(b) or Code Section 743(b) is required
pursuant to Regulations Section 1.704-1(b)(2)(iv)(m)(2) or Section
1.704-1(b)(2)(iv)(m)(4) to be taken into account in determining Capital Accounts
as a result of a distribution to a Partner in complete liquidation of its
Interest, the amount of such adjustment to Capital Accounts shall be treated as
an item of gain (if the adjustment increases the basis of the asset) or loss (if
the adjustment decreases the basis of the asset) and such gain or loss shall be
specially allocated to the Partners in accordance with their Interests in the
Partnership in the event Regulations Section 1.704-1(b)(2)(iv)(m)(2) applies, or
to the Partner to whom such distribution was made in the event Regulations
Section 1.704-1(b)(2)(iv)(m)(4) applies.
4.4.8 ALLOCATIONS RELATING TO TAXABLE ISSUANCE OF INTERESTS
Income, gain, loss or deduction, if any, realized by the
Partnership as a direct or indirect result of the issuance of an Interest by the
Partnership to a Partner (the "Issuance Items") shall be allocated among the
Partners so that, to the extent possible, the Capital Account balance for each
Partner for any Fiscal Year is equal to the Capital Account balance that would
have been maintained for such Partner for such Fiscal Year had the Partnership
not realized the Issuance Items.
4.5 [ * ]
4.6 CODE SECTION 704(C) ALLOCATIONS
In accordance with Code Section 704(c) and the Regulations thereunder,
income, gain, loss and deduction with respect to any property contributed to the
capital of the Partnership shall be allocated among the Partners, solely for
federal income tax purposes, so as to take account of any variation between the
adjusted basis of the property to the Partnership for federal income tax
purposes and its initial Gross Asset Value (computed in accordance with this
Agreement). Such allocations shall be consistently made in accordance with the [
* ] as provided in Regulations Section 1.704-3(c); provided that such [ * ]
shall be limited exclusively to TBC's proportionate share of items of tax
depreciation and amortization deductions attributable to those portions of the
Background Technology [ * ].
In the event the Gross Asset Value of any Partnership asset is adjusted
pursuant to the terms of this Agreement other than as a result of [ * ],
subsequent allocations of income, gain, loss and deduction with respect to such
asset shall take into account any variation between the adjusted basis of such
asset for federal income tax purposes and its Gross Asset Value in a
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-16-
22
manner determined by the Management Committee consistent with Code Section
704(c) and Regulations promulgated thereunder.
4.7 OTHER ALLOCATIONS RULES
(a) For purposes of determining the Profits, Losses or any other
items allocable to any period, Profits, Losses and any such other items shall be
determined on a daily, monthly or other basis, as determined by the Management
Committee using any permissible method under Code Section 706 and the
Regulations thereunder.
(b) Except as otherwise provided in Section 4.6 with respect to
allocations pursuant to Code Section 704(c), for federal income tax purposes,
all allocations of Partnership income, gain, loss or deduction shall be made in
a manner that is consistent with the allocation of Profits and Losses pursuant
to this Article 4. The Partners are aware of the income tax consequences of the
allocations of this Article 4 and hereby agree to be bound by the provisions of
this Article 4 in reporting their allocable shares of Partnership income and
loss for income tax purposes.
(c) Solely for purposes of determining a Partner's proportionate
share of the "excess nonrecourse liabilities" of the Partnership within the
meaning of Regulations Section 1.752-3(a)(3), the Partners' interests in
Partnership profits shall be equal to their respective Partnership Interests.
4.8 TAX MATTERS PARTNER
(a) ICOS-GP shall be the "tax matters partner" (the "Tax Matters
Partner") for the Partnership within the meaning of Code Section 6231(a)(7).
(b) The Tax Matters Partner shall notify and provide copies to the
other Partners within five (5) business days (or as soon as reasonably
practicable thereafter) of any communication received from any governmental
authority regarding any proposed or existing audit, administrative or judicial
proceeding, request for information, preliminary discussion or any other formal
or informal communication regarding any tax matters pertaining to the
Partnership or any Partner. In addition to and not in limitation of the
foregoing, the Tax Matters Partner shall request, pursuant to Code Section 6223,
that the other Partners receive notice from the IRS regarding any proceedings or
adjustments. The Tax Matters Partner shall consult with the other Partners
concerning all tax matters and shall not take any action in connection with any
audit or proceeding, or enter into any agreement with the IRS, that may
adversely affect the other Partners without their express prior written consent.
(c) Notwithstanding anything to the contrary contained in this
Agreement, the Tax Matters Partner shall assure that for the first tax period of
its operations and all subsequent periods of its operation (unless the Partners
have mutually agreed otherwise) the Partnership shall have in effect an election
under Code Section 754 and all applicable regulations thereunder.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-17-
23
ARTICLE 5
DISTRIBUTIONS OF CASH
5.1 DISTRIBUTIONS
5.1.1 LIMITATIONS
Except as provided in Sections 5.3 and 5.4, no distributions
shall be made until the [ * ].
5.1.2 AMOUNT OF DISTRIBUTIONS
Upon meeting the requirements of Section 5.1.1, the Management
Committee shall attempt to minimize the amount of cash and cash equivalents held
by the Partnership yet maintain sufficient funds to operate the Partnership in
accordance with the purposes of the Partnership as stated in Section 2.5. The
Management Committee shall cause the Partnership to distribute on each
Distribution Date, as defined in Section 5.1.3, all amounts that the Management
Committee determines are not necessary to sustain operations of the Partnership
through the following December 31 (the "Distributable Cash"). To determine the
amount of Distributable Cash, the Management Committee shall, prior to each
Distribution Date, determine the amount of funds necessary to sustain operations
of the Partnership through the following December 31 (the "Retained Funds")
based on compliance with an annual operating plan to be developed by the
Management Committee and in consideration of other forecasts. The Retained Funds
shall be that amount of capital necessary to run the business through the
following December 31 considering: [ * ].
5.1.3 TIMING OF DISTRIBUTIONS
Upon meeting the requirements in Section 5.1.1 and considering
the objectives set forth in Section 5.1.2, on or before June 30 and December 31
of each year (the "Distribution Dates"), the Management Committee shall cause
the Partnership to distribute the Distributable Cash expected to be on hand on
such dates (or such other amount as determined by the Management Committee) to
the Partners in proportion to their respective Partnership Interests.
5.2 ADDITIONAL LIMITATIONS ON DISTRIBUTIONS
Except as provided in Section 5.3, no distribution shall be made if it
would render the Partnership insolvent or compromise its ability to operate.
Further, the Management Committee shall not distribute any Property in kind
except upon liquidation of the Partnership.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-18-
24
5.3 [ * ]
5.4 DISTRIBUTION TO PAY TAXES
Notwithstanding Section 5.1 but subject to the limitations on
distributions under Section 5.2, in the event a Partner is allocated an amount
of taxable income for a Fiscal Year (other than the Fiscal Year of the
Partnership's liquidation) in excess of such Partner's proportionate share of
the Partnership's entire taxable income for such year, the Partnership shall
timely distribute to such Partner an amount equal to the effective federal,
state and local income taxes (based on the highest applicable rates in such
year) that would be paid by a corporation recognizing such excess taxable
income. Such distribution shall reduce the Capital Account of the recipient
Partner, but shall not otherwise reduce such Partner's interest in any other
Partnership attribute.
ARTICLE 6
MANAGEMENT AND OPERATION
6.1 MANAGEMENT OF THE PARTNERSHIP
6.1.1 GENERAL PARTNERS
The General Partners, acting jointly, shall have the exclusive
management and control of the affairs of the Partnership and shall have all the
rights and powers of general partners as provided in the Act and as otherwise
provided by law. The General Partners shall exercise their Partnership
management responsibilities through a Management Committee (the "Management
Committee"). Unless expressly and duly authorized in writing to do so by the
Management Committee, no individual General Partner shall (a) have any power or
authority to bind or act on behalf of the Partnership in any way, to pledge its
credit, to execute any instrument on its behalf or to render it liable for any
purpose or (b) delegate any of its power or authority granted under this
Agreement to any Person.
6.1.2 LIMITED PARTNERS
No Limited Partner shall take part in the management or
control of the business of the Partnership nor transact any business in the name
of the Partnership. Except as otherwise expressly provided in this Agreement, no
Limited Partner shall have the power or the authority to bind the Partnership or
to sign any agreement or document in the name of the Partnership. No Limited
Partner shall have any power or authority with respect to the Partnership except
insofar as the consent of any Limited Partner shall be expressly required by the
Act or by this Agreement.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-19-
25
6.2 APPOINTMENT OF COMMITTEE MEMBERS
The business of the Partnership shall be conducted in accordance with
the policies, decisions, guidelines and budgets made or approved by the
Management Committee. The Management Committee shall be composed of six (6)
Committee Members, three (3) of which shall be designated by ICOS-GP (the
"ICOS-GP Committee Members") and three (3) of which shall be designated by
TBC-GP (the "TBC-GP Committee Members"). ICOS-GP may remove any ICOS-GP
Committee Member or fill any vacancy created by the resignation, death or
disability of an ICOS-GP Committee Member and determine the effective date of
such replacement. TBC-GP may remove any TBC-GP Committee Member or fill any
vacancy created by the resignation, death or disability of a TBC-GP Committee
Member and determine the effective date of such replacement. The number of
Committee Members cannot be decreased or increased without the unanimous written
consent of the General Partners. The Management Committee shall appoint one
Committee Member to serve as Chair, who shall serve in such capacity for a term
of two (2) years. The Management Committee shall attempt to alternate between
appointing a ICOS-GP Committee Member and an TBC-GP Committee Member as Chair in
each succeeding term; provided, however, a Committee Member may serve
consecutive terms if so appointed by the Management Committee.
6.3 PERFORMANCE OF DUTIES
Each Committee Member shall perform his or her managerial duties in
good faith, in a manner he or she reasonably believes to be in the best
interests of the Partnership and its Partners, and with such care, including
reasonable inquiry, as an ordinarily prudent person in a like position would use
under similar circumstances. In performing his or her duties, the Committee
Members shall be entitled to rely on information, opinions, reports or
statements, including financial statements and other financial data, of the
following persons or groups, unless they have knowledge concerning the matter in
question that would cause such reliance to be unwarranted and provided that the
Committee Member acts in good faith and after reasonable inquiry when the need
therefor is indicated by the circumstances:
(a) one or more officers, employees or other agents of
the Partnership or a Partner whom the Committee Member reasonably believes to be
reliable and competent in the matters presented; or
(b) any attorney, independent accountant or other person
as to matters that the Committee Member reasonably believes to be within such
person's professional or expert competence.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-20-
26
6.4 DEVOTION OF TIME
A Committee Member is not obligated to devote all of his or her time or
business efforts to the affairs of the Partnership. A Committee Member shall
devote whatever time, effort and skill as he or she deems appropriate for the
operation of the Partnership.
6.5 MEETINGS OF THE MANAGEMENT COMMITTEE
The Management Committee shall meet at least once every quarter. In
addition, the Management Committee shall meet upon the request of any Committee
Member made to the Chair. Committee Members may participate in meetings by means
of audio or video conferencing equipment through which all Committee Members
participating in the meeting can hear each other at the same time, and
participation by such means shall constitute presence in person at a meeting.
Meetings shall be held at such place and time as agreed to by the Management
Committee. The Chair shall provide at least five (5) business days' advance
written notice and an agenda of each meeting of the Management Committee to each
Committee Member, unless a Committee Member waives the advance notice
requirement with respect to that Committee Member. Records of proceedings of the
Management Committee shall be prepared by the Chair and shall be subject to the
approval of the Management Committee.
6.6 ACTION BY COMMITTEE MEMBERS WITHOUT A MEETING
Any action that could be taken at a meeting of the Management Committee
may be taken without a meeting if [ * ].
6.7 QUORUM AND VOTING AT MEETINGS OF COMMITTEE MEMBERS
(a) Quorum. [ * ] shall constitute a quorum of the Management Committee
for the transaction of business.
(b) Voting. Except as provided in Section 6.7(c), any management
decision shall require the approval of the Management Committee, which approval
shall exist only upon the affirmative vote of [ * ] at a meeting of the
Management Committee at which a quorum is present.
(c) Established Policies. The Management Committee may establish
policies and procedures for conducting the normal business of the Partnership
and may delegate to representatives, as approved by the General Partners, the
authority to take actions in accordance with those policies and procedures;
provided, that the following actions will in any event require Management
Committee approval as provided in Section 6.7(b):
(i) Any lending or borrowing of money by the Partnership;
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-21-
27
(ii) The acquisition, mortgage, pledge, sale, assignment,
transfer, license, sublicense or other disposition of any property of the
Partnership having a fair market value in excess of [ * ] by the Partnership
(other than in connection with the sale of products and services in the ordinary
course of its business) or of any interest (regardless of value) in the legal or
beneficial ownership of any other corporation or enterprise;
(iii) The adoption of a business plan or annual capital,
operating and development plans and budgets, including any material modification
thereof ("Business Documents"); and
(iv) Any capital expenditure in excess of [ * ] by the
Partnership.
6.8 OFFICERS; TEAMS/COMMITTEES
The Management Committee may, but is not required to, establish
officers of the Partnership and prescribe the duties of such officers. The
officers of the Partnership shall be chosen by, and shall serve at the pleasure
of, the Management Committee, and shall hold their respective offices until
their resignation, removal or other disqualification from service in a manner
determined by the Management Committee, or until their respective successors
shall be elected. The Management Committee may, but is not required to,
establish such teams or sub-committees composed of representatives from the
Partners or otherwise and delegate to such teams or committees such authority,
duties and responsibilities as it deems appropriate. To assist the Management
Committee in performing its authorized management duties, the Management
Committee expects to establish a "Joint Venture Operating Team," composed of
individuals appointed by the Management Committee, each of whom shall serve for
one (1) year terms and be subject to reappointment by the Management Committee.
The Joint Venture Operating Team shall perform such functions as directed by the
Management Committee.
6.9 INTERNAL CONTROLS
The Management Committee shall conduct the business of the Partnership
at all times in accordance with high standards of business ethics and devise and
maintain a system of internal accounting controls sufficient to provide
reasonable assurances that (a) transactions are executed in accordance with
general or specific authorizations granted by the General Partners and (b)
transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles, to
permit preparation of all tax returns and to maintain accountability for assets
as set forth in Section 14.1.
6.10 FINANCIAL AND BUSINESS INFORMATION AND TAX RETURNS
The Management Committee shall make available to all General Partners
on a regular basis, and as reasonably requested, all such information and/or
documents (including Business Documents as defined in Section 6.7(c)(iii)) as
may be required to permit the Management
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-22-
28
Committee and the General Partners, as the case may be, to make informed
judgments with respect to all matters concerning the Partnership of interest to
them.
6.11 BANK ACCOUNTS
All funds of the Partnership shall be deposited in the name of the
Partnership in such bank accounts as shall be determined by the Management
Committee. No withdrawals for cash may be made in excess of [ * ] at any one
time. Any payment from the accounts may be made or authorized only by an
individual who is so authorized by the Management Committee and approved by the
General Partners; provided, however, that the [ * ] (b) for the purpose of
making any payments to any Partner or its Affiliate. The funds of the
Partnership shall not be commingled with the funds of any other Person, and
neither the Management Committee nor the General Partners shall employ, or
permit any other Person to employ, such funds in any manner except for the
benefit of the Partnership. The General Partners shall not make deposits into or
issue any checks against the Partnership bank accounts without full, proper and
complete supporting records.
6.12 INDEPENDENT ENTERPRISE
The Partners agree to cause the Partnership at all times to be
conducted as an independent enterprise for profit. Except as otherwise agreed to
by the General Partners in writing or provided herein, all commercial
transactions between the Partnership and any Partner (or its Affiliates) shall
be conducted on an arm's-length basis with neither granting to the other terms
or conditions more favorable than would be accorded unrelated third parties,
except as the General Partners otherwise agree in writing prior to such
transactions.
6.13 COMPENSATION
No Committee Member shall be entitled to compensation from the
Partnership for services rendered to the Partnership as Committee Member, except
that the Partnership shall reimburse each Committee Member for reasonable
out-of-pocket expenses incurred by the Committee Member in connection with the
Partnership's business. The previous sentence, however, shall not preclude any
Committee Member from serving the Partnership in any other capacity and
receiving compensation therefor.
6.14 FIDUCIARY DUTY
Each General Partner, Committee Member and officer shall all have the
fiduciary responsibility for the safekeeping and use of all funds and assets
(including records) of the Partnership, whether or not in immediate possession
or control, for the exclusive benefit of the Partnership and its Partners.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-23-
29
6.15 OTHER ACTIVITIES
The Partners may engage in or possess an interest in other business
ventures of any nature or description, independently or with others, whether
presently existing or hereafter created, other than for the purpose of
development, manufacture, production and sale of Endothelin Products in the
Territory.
6.16 NONCOMPETITION
Other than pursuant to the Research and Development Service Agreement,
until dissolution of the Partnership in accordance with Article 13 or purchase
of the Partner's Interest in accordance with this Agreement, no Partner shall,
and each Partner shall cause its Affiliates not to, [ * ].
6.17 CONFLICTS OF INTEREST
The Committee Members who represent any General Partner referred to in
Section 6.2 (the "Interested Partner") shall not be entitled to vote on any
matter that involves (a) a claim by the Partnership against the Interested
Partner or an Affiliate of the Interested Partner; (b) a claim by the Interested
Partner or its Affiliate against the Partnership; (c) the declaration by the
Partnership of a default under any agreement between the Partnership and the
Interested Partner or its Affiliate; (d) the exercise by the Partnership of any
right to terminate any agreement between the Partnership and the Interested
Partner or its Affiliate based on a default thereunder; (e) the negotiation of
any new agreements to be entered into by the Partnership and such Interested
Partner or its Affiliate; or (f) any and all disputes between the Partnership
and the Interested Partner or its Affiliate. As to matters where the
representatives of a Partner are not entitled to vote, the representatives of
the other Partner who are not disqualified may exercise the powers of the
Management Committee in accordance with, and subject to the other provisions of,
this Agreement. Notwithstanding the foregoing, however, no claim shall be
asserted by the Partnership or by an Interested Partner (or its Affiliate)
against the other, and no default shall be declared by the Partnership or an
Interested Partner (or its Affiliate) with respect to the other, unless such
claim or dispute cannot be resolved either by the approval of the Management
Committee as provided under Section 6.7 or under Article 11.
6.18 PATENTS
The Partnership will undertake to [ * ].
6.19 OPERATIONS OUTSIDE THE UNITED STATES
It is expected that structures for doing business outside the United
States in the Territory will be created to enable the achievement of the
purposes set forth in Section 2.5. In establishing the structures, the following
principles and objectives will serve as guidelines:
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-24-
30
(a) [ * ]
(b) [ * ]
(c) [ * ]
(d) [ * ]
6.20 TRADEMARKS
At or shortly after formation the Partners will grant the Partnership a
nonexclusive, royalty free, worldwide license to use the Limited Partners' names
and logos in the name of the Partnership and with the Partnership's products,
product literature (including promotional materials) and services, subject to
the terms of reasonable trademark licenses to be negotiated in good faith.
6.21 RESPONSIBLE PARTY FOR REGULATORY PURPOSES
No later than the [ * ], the Management Committee shall identify a
responsible party and his/her foreign equivalents for the Partnership for the
purposes of meeting health authority requirements. This person will be
considered the most responsible individual within, or on behalf of, the
Partnership for regulatory purposes.
6.22 MARKETING, CO-PROMOTION AND SALES
The Partnership shall establish a marketing and sales plan(s) [ * ].
6.23 MANUFACTURING
The Partnership shall make necessary arrangements to ensure [ * ].
6.24 REGULATORY MATTERS
The Partnership shall use commercially reasonable efforts to [ * ].
ARTICLE 7
RIGHTS, OBLIGATIONS AND POWERS OF THE MEMBERS
7.1 COMPENSATION OF PARTNERS
Except as may be specifically provided in this Agreement or in any
other written agreement, no Partner shall receive any salary, fee or draw for
services rendered to or on behalf of the Partnership.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-25-
31
7.2 SERVICES
7.2.1 TYPES OF SERVICES
The General Partners and their Affiliates expect to provide
the Partnership with business management, accounting and financial support
services in connection with the daily operation of the Partnership's business,
including operating and sales services, in the United States and potentially
throughout the rest of the Territory. Both General Partners or their Affiliates
are expected to provide the Partnership with legal advice and related support
services in connection with filing of patent applications, protection of
intellectual property and support of litigation related to intellectual property
matters and with such other services as the Partnership may require and the
General Partners may agree to provide. The foregoing services that are expected
to be provided to the Partnership shall be subject to the terms of reasonable
service agreements to be negotiated in good faith.
7.2.2 CHARGES FOR SERVICES
Services supplied to the Partnership by the General Partners
or their Affiliates may be charged on the following basis:
(a) Each General Partner may charge the Partnership
[ * ].
(b) If a General Partner retains a third party to
provide consulting or other services to the Partnership, the General Partner may
charge the Partnership for providing such services in the amount that the third
party charges the General Partner, provided such charges are reasonable.
7.3 ADMISSION OF ADDITIONAL PARTNERS
The General Partners, acting jointly, may admit to the Partnership
additional Partners, from time to time, subject to the following:
(a) All the General Partners agree in writing to the admission
of the new Partner;
(b) The additional Partner shall make a Capital
Contribution in such amount and on such terms as the Management Committee
determines to be appropriate; and
(c) No additional Partner shall be admitted if the effect
of such admission would be to terminate the Partnership within the meaning of
Code Section 708(b).
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-26-
32
ARTICLE 8
LIMITATION UPON LIABILITY; INDEMNIFICATION
8.1 LIMITATION UPON LIABILITY OF LIMITED PARTNERS
The liability of each Limited Partner shall be limited to its Capital
Contributions as and when payable under the provisions of this Agreement, and as
provided under the Act. No Limited Partner shall have any other liability to
contribute money to, or in respect of the liabilities or obligations of, the
Partnership, nor shall any Limited Partner be personally liable for any
obligations of the Partnership, except as and to the extent provided in the Act.
No Limited Partner shall be obligated to make loans to the Partnership.
8.2 INDEMNIFICATION BY PARTNERSHIP
The Partnership shall indemnify and hold harmless all Partners,
Committee Members, officers, their Affiliates and authorized agents of the
Partnership (an "indemnitee") against any liability, loss, damage, cost or
expense (including attorneys' fees and costs) incurred by an indemnitee on
behalf of the Partnership or in furtherance of the Partnership's interests;
provided, however, that the Partnership shall not indemnify and hold harmless an
indemnitee in any of the circumstances under which such indemnification is not
allowed under the Act. Any indemnification required hereunder shall be made
promptly as the liability, loss or expense is incurred or suffered, and the
indemnification provided by this Section 8.2 shall be in addition to any other
rights to which those indemnified may be entitled under any agreement, as a
matter of law or equity, or otherwise, and shall continue as to a Partner,
Committee Member or officer who has ceased to serve in that capacity, and shall
inure to the benefit of the heirs, successors, assigns and administrators of the
indemnitees.
ARTICLE 9
REPRESENTATIONS AND WARRANTIES
9.1 REPRESENTATIONS AND WARRANTIES
Each Partner hereby represents and warrants to the other Partners as of
the date hereof the following:
9.1.1 ORGANIZATION AND EXISTENCE
Such Partner is a corporation duly organized, validly existing
and in good standing under the laws of the jurisdiction in which it was
incorporated.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-27-
33
9.1.2 POWER AND AUTHORITY
Such Partner has the full power and authority to execute,
deliver and perform this Agreement, and to own and lease its properties and to
carry on its business as now conducted and as contemplated hereby.
9.1.3 AUTHORIZATION AND ENFORCEABILITY
The execution and delivery of this Agreement by such Partner
and the carrying out by such Partner of the transactions contemplated hereby
have been duly authorized by all requisite corporate and limited liability
company actions, and this Agreement has been duly executed and delivered by such
Partner and constitutes the legal, valid and binding obligation of such Partner,
enforceable against it in accordance with the terms hereof, subject, as to
enforceability of remedies, to limitations imposed by bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to or affecting the
enforcement of creditors' rights generally and general principles of equity.
9.1.4 NO GOVERNMENTAL CONSENTS
No authorization, consent or approval of, or notice to or
filing with, any governmental authority is required for the execution, delivery
and performance by such Partner of this Agreement.
9.1.5 NO CONFLICT OR BREACH
None of the execution, delivery and performance by such
Partner of this Agreement, the compliance with the terms and provisions hereof,
and the carrying out of the transactions contemplated hereby conflicts or will
conflict with or will result in a breach or violation of any of the terms,
conditions or provisions of any law, governmental rule or regulation or the
charter documents, as amended, or bylaws, as amended, of such Partner or any
order, writ, injunction, judgment or decree of any court of governmental
authority against such Partner or by which it or any of its proprieties is
bound, or any loan agreement, indenture, mortgage, note, resolution, bond, or
contract or other agreement or instrument to which such Partner is a party or by
which it or any of its properties is bound, or constitutes or will constitute a
default thereunder or will result in the imposition of any lien upon any of its
properties.
9.1.6 NO PROCEEDINGS
There are no suits or proceedings pending, or to the knowledge
of such Partner, threatened in any court or before any regulatory commission,
board or other governmental administrative agency against or affecting such
Partner that could have a material adverse effect on the business or operations
of such Partner, financial or otherwise, or on its ability to fulfill its
obligations hereunder.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-28-
34
9.1.7 NO ENDOTHELIN AGENTS
Except for EtRAs and the other compounds included in the
Endothelin License Agreement with respect to TBC and to each Partner's knowledge
and the knowledge of its Affiliates, such Partner and its Affiliates (a) [ * ]
(b) [ * ] and (c) are not selling any product that contains an Endothelin Agent
or conducting any clinical trial of an Endothelin Agent. [ * ].
9.2 ADDITIONAL REPRESENTATIONS AND WARRANTIES OF TBC
TBC hereby represents and warrants to the Partners as of the date
hereof, subject to the Endothelin License Agreement, that (a) it owns or
controls the Background Technology (except technology that is not the subject of
patents), (b) the Background Technology is free and clear of any liens, claims
or encumbrances other than pursuant to the LG Chem License described in Section
3.4, (c) [ * ] (d) to its knowledge, there is no material and unauthorized use,
infringement or misappropriation of any of its rights in the Background
Technology, (e) it has provided to ICOS Corporation a complete and accurate copy
of all third party agreements associated with the Background Technology, (f) set
forth in Attachment A to the Endothelin License Agreement is a complete listing
of patents, patent applications and invention disclosures that are owned by TBC
relating to the Background Technology, (g) [ * ].
9.3 WARRANTY OF STATEMENTS
No representation or warranty of any Partner, or any exhibit, document,
statement, certificate or schedule pursuant hereto or in connection with the
transactions contemplated hereby, contains or will contain any untrue statement
of a material fact, or omits or will omit to state a material fact necessary to
make statements or facts contained therein not misleading. The representations
and warranties of the Partners set forth in this Agreement and in any exhibit,
document, statement, certificate or schedule furnished or to be furnished
pursuant hereto shall be true on and as of the Effective Date as though such
representations and warranties were made on and as of Effective Date.
9.4 SURVIVAL OF REPRESENTATIONS AND WARRANTIES
The respective representations and warranties of the Partners shall
survive the Effective Date and continue in full force and effect for a period
thereafter equal to five (5) years following the Effective Date.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-29-
35
ARTICLE 10
INDEMNIFICATION
10.1 INDEMNIFICATION
Each Partner (the "Indemnifying Partner") shall indemnify and hold the
other Partners, the Partnership and their respective Affiliates, Committee
Members, officers, employees and agents harmless from and against any and all
claims, liabilities, losses, costs, damages and expenses, including costs of
investigation, court costs and reasonable attorneys' fees, to which any of them
may become subject arising from or in any manner connected with, directly or
indirectly, any material misstatement, error or omission in any representation
or warranty of the Indemnifying Partner contained in this Agreement (without
effect on the Indemnifying Partner's liability under the various instruments and
documents to be executed in connection herewith).
10.2 MECHANISM FOR INDEMNIFICATION
The Partner seeking indemnification hereunder ("Indemnified Partner")
shall give written notice to the Indemnifying Partner of its indemnification
claims hereunder, specifying the amount and nature of the claim, and giving the
Indemnifying Partner the right to contest any such claim represented by counsel
of its choice; if any such claim is made hereunder by the Indemnified Partner
and such claim arises from the claims of a third party against the Indemnified
Partner and the Indemnifying Partner does not elect to undertake the defense
thereof by written notice within fifteen (15) days after receipt of the original
notice from the Indemnified Partner, the Indemnified Partner shall be entitled
to indemnity pursuant to the terms of this Agreement to the extent of its
payment in respect of such claim. To the extent that the Indemnifying Partner
undertakes the defense of such claim in good faith by proceeding diligently at
its expense, and without materially impairing the financial conditions or
operations of the Indemnified Partner, the Indemnified Partner shall be entitled
to indemnity hereunder only if, and to the extent that, such defense is
unsuccessful as determined by a final judgment of a court of competent
jurisdiction or is settled with the consent of the Indemnifying Partner. The
Partner defending a third-party claim shall have the right to choose its own
counsel.
ARTICLE 11
DISPUTE RESOLUTION
11.1 DISPUTE
Except as provided in Section 2.5.2, in the event a dispute arises
between the Partners regarding the application or interpretation of any
provision of this Agreement or if there is a deadlock among the Committee
Members or the General Partners with respect to any management decision (a
"Dispute" for purposes of this Article 11 only), then upon the written request
of any Partner that includes a summary of the Dispute, [ * ].
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-30-
36
11.2 MEDIATION
Except as provided in Section 2.5.2, any Dispute that the Partners are
unable to resolve through [ * ] shall be submitted to nonbinding mediation,
which will be held in Houston, Texas, if initiated by either ICOS Partner and in
Seattle, Washington, if initiated by either TBC Partner. The Partners will
mutually determine the mediator from a list of mediators obtained from the
American Arbitration Association office located in the city in which the
proceeding will take place. If the Partners are unable to agree on the mediator,
the mediator will be selected by the American Arbitration Association with a
preference for selecting a retired federal judge or state supreme court judge as
the mediator.
ARTICLE 12
TRANSFERS OF MEMBERSHIP INTERESTS
12.1 OVERALL RESTRICTIONS
The Partnership will be owned on the Effective Date by four (4)
entities that have the compatibility and financial stability that are major
elements contributing toward the prospect of the future success of the
Partnership. Except in accordance with the terms of this Agreement, no Partner
shall Transfer all or any part of its Partnership Interest, or any interest
therein, unless the Partner (a) obtains the prior written consent of each
General Partner, which consent may be withheld in the sole and absolute
discretion of each General Partner, and (b) provides satisfactory evidence to
the Partnership that such Transfer shall not violate applicable securities laws.
Unless such prior requirements are met, the proposed Transfer may not take
place, and any attempted Transfer in derogation hereof shall be deemed null and
void. [ * ] If for any reason any clause or provision of this Section 12.1
should be held unenforceable, invalid or in violation of law by any court or
tribunal, then the non-Transferring Partners shall have the right, exercisable
in writing within ninety (90) days of the date of final determination of
invalidity or unenforceability, to purchase the Partnership Interest purported
to be Transferred, pursuant to the terms of Section 12.3.
12.2 ADDITIONAL RESTRICTIONS ON THE LIMITED PARTNERS
12.2.1 EVENT INVOLVING ICOS-LP
Upon the occurrence of any of the following events with
respect to ICOS-LP or its parent company: (a) any transfer of substantially all
of its assets, (b) a liquidation or dissolution, or (c) any insolvency or
bankruptcy proceeding, then TBC shall have the right, exercisable in writing
within sixty (60) days after the later of (i) receipt of written notice of the
occurrence of such event and (ii) the conclusion of the appraisal contemplated
in Section 12.3, to purchase all Partnership Interests held by both ICOS
Partners pursuant to the terms of Section 12.3 or to dissolve the Partnership
pursuant to the terms of Article 13. ICOS-LP shall notify TBC in
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-31-
37
writing of any occurrence described in clauses (a), (b) or (c) of this Section
12.2.1 at the earliest time practicable.
12.2.2 EVENT INVOLVING TBC
Upon the occurrence of any of the following events with
respect to TBC: (a) any transfer of substantially all of its assets, (b) a
liquidation or dissolution, or (c) any insolvency or bankruptcy proceeding, then
ICOS-LP shall have the right, exercisable in writing within sixty (60) days
after the later of (i) receipt of written notice of the occurrence of such event
and (ii) the conclusion of the appraisal contemplated in Section 12.3, to
purchase all Partnership Interests held by both TBC Partners pursuant to the
terms of Section 12.3 or to dissolve the Partnership pursuant to the terms of
Article 13. TBC shall notify ICOS-LP in writing of any occurrence described in
clauses (a), (b) or (c) of this Section 12.2.2 at the earliest time practicable.
12.3 PURCHASE PRICE AND PAYMENT DATE
The purchase price to be paid for either (a) the Partnership Interest
of the transferring Partner described in Section 12.1 or (b) the Partnership
Interests of the respective Partners described in Section 12.2, shall be
computed as follows:
(a) Within sixty (60) days after the occurrence of an
event described in Section 12.1 or 12.2, the Limited Partners shall jointly
appoint an investment banking firm or failing this joint action, each Limited
Partner shall designate an investment banking firm. Within thirty (30) days
after their appointment, the two designated investment banking firms shall
designate a third investment banking firm (the "Neutral Investment Banker"). The
failure by any Limited Partner to appoint an investment banking firm within the
time allowed shall be deemed equivalent to appointing the other Limited
Partner's investment banking firm as the jointly appointed investment banking
firm. Within sixty (60) days after the appointment of the jointly appointed
investment banking firm or the Neutral Investment Banker, as the case may be,
the jointly appointed investment banking firm or the Neutral Investment Banker,
as the case may be, shall render its appraisal of the fair market value of the
Partnership Interest(s) being purchased, which appraisal shall be binding and
conclusive. The Partnership shall bear all appraisal expenses.
(b) The payment date of the purchase price pursuant to
this Section 12.3 shall not be later than sixty (60) days after the sixty (60)
day period set forth in Section 12.3(a).
12.4 CHANGE IN CONTROL
12.4.1 ICOS-LP
In the event of a Change in Control of either of the ICOS
Partners or their parent company, TBC shall be [ * ], except (a) all accrued
obligations shall survive, (b) the provisions
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-32-
38
of Sections 2.7, 3.2.3 and 5.3 and Articles 10 and 11 shall survive, (c) the
Endothelin License Agreement will not terminate, and (d) Article 6 of the
Research and Development Service Agreement shall survive but shall not operate
as to any future developments, inventions or discoveries.
12.4.2 TBC
In the event of a Change in Control of either of the TBC
Partners, ICOS-LP shall [ * ], except (a) all accrued obligations shall survive,
(b) the provisions of Sections 2.7, 3.2.3 and 5.3 and Articles 10 and 11 shall
survive, (c) the Endothelin License Agreement will not terminate, and (d)
Article 6 of the Research and Development Service Agreement shall survive but
shall not operate as to any future developments, inventions or discoveries.
12.4.3 DEFINITION
A "Change in Control" occurs when (a) any Person becomes,
after the date hereof, the beneficial owner, directly or indirectly, of more
than [ * ] of the outstanding securities of a Partner or (b) any Partner is
involved in a reorganization, merger or consolidation, except a "Change in
Control" will not have occurred if, after the transaction, [ * ] or more of the
outstanding voting securities of the entity acquiring the Partner's voting
securities or resulting or surviving from the reorganization, merger or
consolidation are owned by the Partner's shareholders in the same proportion as
they owned the Partner's voting securities immediately prior to such
transaction.
12.5 ADMISSION OF SUBSTITUTED PARTNERS
Subject to the other provisions of this Section 12, a transferee of a
Partnership Interest may be admitted to the Partnership as a substituted Partner
only upon satisfaction of the following conditions:
(a) The Partners unanimously consent to such admission,
which consent may be given or withheld in the sole discretion of each Partner;
(b) The transferee becomes a party to this Agreement as a
Partner and executes such documents and instruments as the Management Committee
and General Partners may reasonably request as may be necessary or appropriate
to confirm such transferee as a Partner and bind such transferee by the terms
and conditions of this Agreement; and
(c) The transferee pays or reimburses the Partnership for
all reasonable legal, filing and publication costs that the Partnership incurs
in connection with the admission of the transferee as a Partner with respect to
the transferred Interest.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-33-
39
12.6 SPECIFIC PERFORMANCE
Each of the Partners acknowledges that the rights and obligations
provided by this Section 12 are of unique value to it and that the payment of
monetary damages could not adequately compensate the other Partner for any
breach of the obligations set forth herein. Accordingly, the rights of the
Partners set forth in this Section 12 shall be specifically enforceable in
accordance with their terms.
ARTICLE 13
SALE, DISSOLUTION AND LIQUIDATION
13.1 EVENTS OF DISSOLUTION
The Partnership shall be dissolved only upon the following events:
(a) The mutual written consent of the Limited Partners.
(b) Upon the occurrence of any of the events set forth in Section
12.2 if the Partner that is not subject to the occurrence of the stated event
shall not have exercised the purchase option provided in Section 12.2 and shall
have requested, within sixty (60) days after such occurrence, that the
Partnership be dissolved.
(c) By either Limited Partner upon the bankruptcy, receivership or
insolvency of the other Limited Partner or the Partnership, or upon the material
breach of this Agreement by the other Limited Partner; provided, however, that
such dissolution shall be with respect to federal and Delaware income tax
purposes, but preserved in nominal form for Delaware state law purposes.
(d) The occurrence of an Event of Withdrawal of a General Partner,
unless the Limited Partners agree within thirty (30) days of such event not to
dissolve the Partnership.
In addition, the Partners recognize that the Partnership may be
dissolved by order of a court of competent jurisdiction pursuant to Section
17-802 of the Act.
13.2 FINAL ACCOUNTING AND TAX RETURNS
Upon the dissolution of the Partnership, a complete and accurate
accounting shall be made by the Partnership's independent certified public
accountants from the date of the last previous accounting to the date of
dissolution, and all required tax returns shall be timely filed in connection
therewith.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-34-
40
13.3 LIQUIDATION
Upon the dissolution of the Partnership, each General Partner shall
appoint an individual to act as a liquidator to wind up the Partnership (and, if
either General Partner fails to appoint such individual within sixty (60) days
after the written request of the other General Partner, the individual that
shall have been appointed by such other General Partner within such sixty (60)
day period shall act as the liquidator) (the individuals so appointed shall be
referred to collectively as the "Liquidator"). The Liquidator shall have full
power and authority to take full account of the Partnership's assets and
liabilities and to wind up and liquidate the affairs of the Partnership in an
orderly and business-like manner as is consistent with obtaining the fair value
thereof upon dissolution. The Partnership shall engage in no further business
thereafter other than as necessary to operate on an interim basis, collect its
receivables, pay its liabilities and liquidate its assets.
13.4 DISTRIBUTIONS IN LIQUIDATION
(a) Upon dissolution of the Partnership and the liquidation of the
assets of the Partnership pursuant to this Article 13, the Liquidator shall wind
up the affairs of the Partnership and liquidate the Property as promptly as is
consistent with obtaining fair value therefor and cause the remaining Property,
including proceeds of sales or other dispositions in liquidation of Property, to
be applied in accordance with the following priorities:
(i) First, to payment of the debts and obligations of the
Partnership to its creditors (including to the Partners that are creditors), to
the extent otherwise permitted by law, in satisfaction of liabilities of the
Partnership (whether by payment or the making of reasonable provision for
payment thereof) other than liabilities for which reasonable provision for
payment has been made and liabilities for distributions to Partners and former
Partners under Sections 17-601 or 17-604 of the Act;
(ii) Second, to the establishment of such reserves as required
by Section 17-804(b) of the Act for the purposes as stated therein;
(iii) Third, to the Partners having positive Capital Accounts
pro rata in accordance with their relative positive Capital Accounts (as
determined after taking into account all Capital Account adjustments for the
Partnership's Fiscal Year during which such liquidation occurs), until all such
positive Capital Accounts are reduced to zero; and
(iv) Fifth, among the Partners in proportion to their
respective Partnership Interests.
The reserves established pursuant to clause (ii) of this Section 13.4(a) shall
be paid over by the Liquidator to a bank or other financial institution to be
held in escrow for the purpose of paying unliquidated, contingent or unforeseen
liabilities or obligations, and, at the expiration of such
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-35-
41
period as the Liquidator deems advisable, and in compliance with the
requirements of the Act, such reserves shall be distributed to the Partners or
their assigns in the priority set forth in clauses (iii) and (iv) of this
Section 13.4(a). Distributions to the Partners pursuant to this Section 13.4(a)
shall be made within the time period prescribed by Regulations Section
1.704-1(b)(2)(ii)(b).
(b) In the event the Liquidator determines that an immediate sale
of part or all of the Partnership assets would cause undue loss to the Partners,
the Liquidator, in order to avoid such loss, may either (i) defer liquidation of
any assets of the Partnership for a reasonable time, except those assets
necessary to satisfy Partnership debts and obligations, or (ii) distribute the
assets in kind to the Partners. If any assets of the Partnership are to be
distributed in kind, such assets shall be valued and shall be deemed sold at
their fair market value and any gain or loss deemed realized shall be allocated
to the Capital Accounts of the Partners for purposes of applying this Section
13.4 as if such gain or loss had actually been fully realized. Any assets that
are to be so distributed shall be distributed on the basis of the fair market
value thereof and any Partner entitled to an interest in such assets shall
receive such interest therein as a tenant-in-common with all other Partners so
entitled. The fair market value of such assets shall be determined by an
appraiser to be selected by the Liquidator or by agreement of all the Partners.
In the event of such distribution in kind, the distributee Partner shall not
thereafter sell or otherwise Transfer or dispose of any interest in any assets
so distributed which it holds as a tenant-in-common without first offering such
interest in writing to the other tenant-in-common upon the same terms and
conditions and for the same price as such proposed sale or Transfer. The other
tenant-in-common shall have thirty (30) days after the receipt of such offer
within which to accept the same and shall have the right to acquire such
interest. If the other tenant-in-common shall fail to accept such offer within
such period of time, such distributee Partner shall be free to sell the interest
in such assets upon the terms and conditions described in the offer disclosed to
the other tenants-in-common free of any further rights of first refusal.
13.5 DEFICIT CAPITAL ACCOUNTS
(C)Except as may otherwise be required by law, notwithstanding anything
to the contrary contained in this Agreement, to the extent that any Partner has
a deficit Capital Account balance upon dissolution of the Partnership, that
balance shall not be an asset of the Partnership and that Partner shall not be
obligated to contribute any amount to the Partnership to bring the balance of
that Partner's Capital Account to zero.
13.6 TERMINATION OF PARTNERSHIP AND AGREEMENT
Upon the completion of the distributions in liquidation of the
Partnership as provided in this Article 13, (a) the Liquidator shall take all
actions as may be appropriate to finally dissolve and liquidate the Partnership
and (b) this Agreement shall terminate.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-36-
42
ARTICLE 14
ACCOUNTING AND REPORTS
14.1 BOOKS AND RECORDS
(a) Procedures. The Management Committee shall implement standard
procedures with respect to accounting, financial reporting and management
information, including, without limitation, statements reflecting Partnership
distributions, earnings, Profits and Losses, residual value of Partnership
Property and taxable income.
(b) Records. At all times during the term of the Partnership, the
Management Committee shall keep or cause to be kept full and accurate books,
records and accounts, which shall, in reasonable detail, accurately and fairly
reflect each transaction of the Partnership; provided, however, that at a
minimum the Management Committee shall, on behalf of the Partnership, maintain
such records as listed in Section 17-305(a) of the Act. Each Partner and its
representatives shall have access to such books, records and documents during
reasonable business hours and may inspect and make copies of any of them. The
Management Committee may delegate to a third party or General Partner the duty
to maintain and oversee the preparation of such records and books of account.
The Management Committee shall maintain all such books and records for the six
(6) most recent Fiscal Years or until such year is closed for tax audit
purposes.
(c) Audit of Partnership's Statements. The Partnership will engage
and pay for an external accounting firm to audit its financial statements at
least annually. Since it is anticipated that one General Partner, as chosen by
the Management Committee (the "Accounting Services Provider"), will provide
accounting services to the Partnership, the Management Committee is advised
that, whenever practicable, it should appoint the primary external accounting
firm which provides services to the Accounting Services Provider. The General
Partner which is not the Accounting Services Provider shall have the right,
during regular business hours and upon reasonable advance notice, to review the
audited financial statements and the related work papers and findings of the
external accounting firm supporting the financial statements or request another
external accounting firm to perform such examination, the cost of which shall be
borne by the party requesting the examination.
(d) Examination of Partner Transactions. Each Partner shall keep
comprehensive books and records relating to (i) such Partner's reimbursements
under this Agreement and (ii) any compensation or reimbursements under any
agreement with the Partnership, on a full accrual basis of accounting in
accordance with generally accepted accounting principles for the three (3) most
recent Fiscal Years. Either Partner, upon reasonable advance notice to the other
Partner, may examine or engage an external accounting firm to examine the
accuracy of revenues, ▇▇▇▇▇▇▇▇ and supporting documentation of the other Partner
for services or payments to or from the Partnership during the prior three (3)
Fiscal Years, including under the Research and
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-37-
43
Development Service Agreement and any other agreements involving the Partnership
and the other Partner. The Partner requesting the review shall, for purposes of
such review, utilize the other Partner's regular outside certified public
accounting firm. The cost of such examination shall be borne by the Partner
requesting the examination; however, in the event such examination reveals
information that deviates by [ * ] or more from the information previously
provided to the Partner requesting the examination, the cost of the examination
shall be borne by the other Partner.
14.2 ACCOUNTING METHOD
The books and records of the Partnership shall be kept in accordance
with generally accepted accounting principles and methods applied on a
consistent basis from year to year.
14.3 FISCAL YEAR
The Partnership shall use the calendar year as its fiscal year for all
financial reporting and tax purposes (the "Fiscal Year").
14.4 REPORTS; TAX RETURNS
Copies of all accounts, reports and other writings pertaining to the
business of the Partnership furnished by a Partner, the Partnership or the
Partnership's accountants to any Partner or regulatory agency shall
contemporaneously be delivered to all Partners.
On a periodic basis, the Partnership shall submit to the Partners the
following financial information:
(a) [ * ]
(b) [ * ]
(c) [ * ]
Calendars and subsequent revisions thereto, if any, referred to above
will be provided to the Partnership within ten (10) days of their publication
and distributions within ICOS-GP.
Prior to March 15 of each year, the Management Committee shall provide
to the Partners regular annual audited financial statements prepared by
independent, nationally recognized certified public accountants as chosen under
Section 14.1(c), which shall include a statement of profits and losses, changes
in financial position and a balance sheet for the year then ended, as well as
such other appropriate financial information reasonably requested by the
Management Committee or Partners.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-38-
44
The Management Committee shall cause to be prepared and filed, on the
Partnership's behalf and at the Partnership's expense, all federal, state and
other tax returns required to be filed, and shall submit the same to the
Partners for review and approval not less than thirty (30) days prior to the
respective due dates for such returns (including any extensions thereof), but,
with respect to the Partnership's United States federal income tax information
return, in no event later than May 15 of each year. Apportionment data for state
returns will be provided by June 1 of each year.
14.5 REQUIRED GOVERNMENTAL FILINGS
The Management Committee shall cause the Partnership to file, on or
before the dates the same may be due, giving effect to extensions obtained, all
reports, returns and applications that may be required by any governmental or
quasi-governmental body having jurisdiction.
ARTICLE 15
GENERAL PROVISIONS
15.1 NOTICES
Any notice, request, instruction or other document to be given
hereunder by a Partner to another Partner hereto shall be in writing, delivered
in person, or mailed by certified or registered mail, return receipt requested,
or transmitted by facsimile transmission with electronic confirmation of receipt
to the addressee's address or facsimile number set forth below (or such other
address or facsimile number as the party changing its address specifies in a
notice to the other parties):
If to ICOS-LP or ICOS-GP:
ICOS Corporation
▇▇▇▇▇ - ▇▇▇▇ ▇▇▇▇▇▇ ▇.▇.
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: President
Phone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
with a copy to:
▇▇▇▇▇▇▇ Coie LLP
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
Attention: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, Esq.
Phone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-39-
45
If to TBC or TBC-GP:
Texas Biotechnology Corporation
▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: President
Phone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
with a copy to:
▇▇▇▇▇▇ & ▇▇▇▇▇▇, L.L.P.
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Esq.
Phone: (▇▇▇) ▇▇▇-▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Notices shall be deemed to have been given on the date of service, if served
personally on the party to whom notice is to be given, or on the first day after
transmission by facsimile transmission, if transmitted by facsimile as set forth
above, or on the fifth day after mailing, if mailed as set forth above.
15.2 WAIVER
No waiver of any breach of the terms of this Agreement shall be
effective unless such waiver is in writing and signed by the Partner against
whom such waiver is claimed. No waiver of any breach shall be deemed to be a
waiver of any other or subsequent breach.
15.3 SEVERABILITY
If any provision of this Agreement shall be held to be invalid, illegal
or unenforceable, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.
15.4 WAIVER OF PARTITION
No Partner, either directly or indirectly, shall take any action to
require partition of the Partnership or any of its assets or properties.
Notwithstanding any provisions of applicable law to the contrary, each Partner
(and its successors and assigns) hereby irrevocably waives any and all right to
maintain any action for partition or to compel any sale with respect to its
Partnership Interest, or with respect to any assets or properties of the
Partnership, except as expressly provided in this Agreement.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-40-
46
15.5 FURTHER ASSURANCES
Each Partner shall execute such deeds, assignments, endorsements,
evidences of transfer and other instruments and documents and shall give further
assurances as shall be necessary to perform its obligations hereunder and shall
execute such estoppel and other documents as are reasonably requested by any
other Partner regarding the status of the Partnership.
15.6 GOVERNING LAW
This Agreement shall be governed by and construed in accordance with
the laws of the State of Delaware, without regard to the choice of law
provisions of the State of Delaware or any other jurisdiction.
15.7 COUNTERPARTS
This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original, but all of which shall constitute one and the
same instrument.
15.8 LIMITATION ON RIGHTS OF OTHERS
This Agreement is entered into between the Partners for the exclusive
benefit of the Partnership, its Partners, and their successors and permitted
assigns. This Agreement is not intended for the benefit of any creditor of the
Partnership or any other Person. Except to the extent provided by applicable
statute, and then only to that extent, no creditor or third party shall have any
rights under this Agreement or under any other agreement between the Partnership
and any Partner with respect to any contribution to the Partnership or
otherwise.
15.9 SUCCESSORS AND ASSIGNS
This Agreement shall be binding on and inure to the benefit of the
Partners and their respective successors and permitted assigns.
15.10 ENTIRE AGREEMENT; AMENDMENT
This Agreement constitutes the entire agreement between the Partners
with respect to the subject matter hereof and supersedes all prior agreements
and understandings, whether oral or written, between the Partners (and their
Affiliates) with respect to the subject matter hereof, including the two
Confidential Disclosure Agreements (CDAs) dated [ * ] and [ * ] between ICOS
Corporation and TBC regarding confidential information (which is superseded and
replaced by Section 2.7). This Agreement may be amended only in writing signed
by all the Partners.
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-41-
47
15.11 EXPENSES
Except as otherwise provided herein or agreed to in writing by the
Partners or their Affiliates, each Partner shall bear its own costs and
expenses, including legal fees, associated with carrying on its business as a
Partner hereof.
15.12 CONSTRUCTION
This Agreement has been submitted to the scrutiny of, and has been
negotiated by, all Partners hereto and their counsel, and shall be given a fair
and reasonable interpretation in accordance with the terms hereof, without
consideration or weight being given to its having been drafted by any party
hereto or its counsel.
15.13 DISCLAIMER OF AGENCY
This Agreement does not create any entity or relationship beyond the
scope set forth herein, and except as otherwise expressly provided herein, this
Agreement shall not constitute any Partner the legal representative or agent of
the other, nor shall any Partner or any Affiliate of a Partner have the right or
authority to assume, create or incur any liability or obligation, express or
implied, against, in the name of or on behalf of any other Partner, its
Affiliates, the Partnership or its Affiliates.
15.14 RIGHTS AND REMEDIES
The rights and remedies provided by this Agreement are cumulative and
the use of any one right or remedy shall not preclude or waive the right to use
any or all other remedies. These rights and remedies are given in addition to
any other rights, other than the right of partition, the Partners may have by
law, statute, ordinance or otherwise.
15.15 ATTORNEYS' FEES
In the event of a dispute between the Committee Member and Partners, or
the Partners, arising out of this Agreement that is arbitrated or litigated and
except as decided by the arbitrators under Section 2.5, the nonprevailing party
shall pay the reasonable costs and attorneys' fees of the prevailing party,
including the reasonable costs and attorneys' fees incurred in the appeal of any
final or interlocutory judgment.
[signatures on following page]
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-42-
48
IN WITNESS WHEREOF, the Partners hereto have executed this Agreement as
of the day and year first above written.
GENERAL PARTNERS:
ICOS-ET-GP LLC
By: /s/ ▇▇▇▇ ▇▇▇▇▇
Name: ▇▇▇▇ ▇▇▇▇▇
Title: Chairman & CEO
TBC-ET, INC.
By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
Title: President
LIMITED PARTNERS:
ICOS-ET-LP LLC
By: /s/ ▇▇▇▇ ▇▇▇▇▇
Name: ▇▇▇▇ ▇▇▇▇▇
Title: Chairman & CEO
TEXAS BIOTECHNOLOGY CORPORATION
By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
Title: President/CEO
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
-43-
49
EXHIBIT A
ENDOTHELIN LICENSE AGREEMENT
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
50
EXHIBIT B
RESEARCH AND DEVELOPMENT SERVICE AGREEMENT
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
51
EXHIBIT C
PRESS RELEASE
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.
52
EXHIBIT D
[ * ]
[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.